Fmr LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,039,884 shares of the biopharmaceutical company’s stock after purchasing an additional 416,192 shares during the quarter. Fmr LLC owned about 6.67% of Regeneron Pharmaceuticals worth $3,457,569,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Oppenheimer & Co. Inc. raised its holdings in Regeneron Pharmaceuticals by 20.6% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock worth $3,441,000 after purchasing an additional 1,199 shares during the last quarter. Dupont Capital Management Corp bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $220,000. Blair William & Co. IL raised its holdings in Regeneron Pharmaceuticals by 4.8% during the 2nd quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock worth $841,000 after purchasing an additional 79 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Regeneron Pharmaceuticals by 2.4% during the 2nd quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock worth $56,580,000 after purchasing an additional 2,646 shares during the last quarter. Finally, National Pension Service raised its holdings in Regeneron Pharmaceuticals by 10.8% during the 2nd quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock worth $33,920,000 after purchasing an additional 6,481 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
In related news, SVP Robert E. Landry sold 663 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $498.60, for a total transaction of $330,571.80. Following the transaction, the senior vice president now owns 10,099 shares of the company’s stock, valued at $5,035,361.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders sold 85,968 shares of company stock valued at $40,699,948 in the last three months. Insiders own 10.40% of the company’s stock.
Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Piper Jaffray Companies boosted their target price on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 20th. BMO Capital Markets restated a “market perform” rating and set a $484.00 target price (up from $421.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Leerink Swann restated an “outperform” rating and set a $493.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, June 13th. Finally, Sanford C. Bernstein lowered Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $410.00 to $480.00 in a research report on Monday, June 26th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $491.43.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded down 0.81% during midday trading on Thursday, hitting $434.63. The stock had a trading volume of 122,354 shares. The company’s 50 day moving average is $468.97 and its 200 day moving average is $447.18. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55. The firm has a market cap of $46.09 billion, a P/E ratio of 43.60 and a beta of 1.65.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter last year, the firm posted $2.82 earnings per share. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.89 earnings per share for the current fiscal year.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.